378 related articles for article (PubMed ID: 9273812)
41. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe.
Benevento A; Dominioni L; Carcano G; Dionigi R
Semin Surg Oncol; 1998 Dec; 15(4):239-44. PubMed ID: 9829380
[TBL] [Abstract][Full Text] [Related]
42. [Somatostatin receptor scintigraphy. Methodology, indications, results].
Eising EG; Bier D; Knust EJ; Reiners C
Radiologe; 1996 Jan; 36(1):81-8. PubMed ID: 8820376
[TBL] [Abstract][Full Text] [Related]
43. Detection of medullary carcinoma of thyroid, with liver metastasis, using 99mTc DMSA(V) scintigraphy.
Shikare S; Bashir K; Menon PS; Bapat RD; Tilve GH
J Postgrad Med; 1995; 41(1):12-3. PubMed ID: 10740693
[TBL] [Abstract][Full Text] [Related]
44. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
45. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
46. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
47. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B
Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522
[TBL] [Abstract][Full Text] [Related]
48. [Preoperative cytological diagnosis of Sipple syndrome].
Bondarenko IO; Shapiro NA; Bogin IuN; Orlov VM; Karagulian RG; Berkovich SI
Klin Med (Mosk); 1995; 73(2):56-8. PubMed ID: 7609423
[No Abstract] [Full Text] [Related]
49. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
50. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
51. Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization.
Jensen RT; Gibril F; Termanini B
Yale J Biol Med; 1997; 70(5-6):481-500. PubMed ID: 9825476
[TBL] [Abstract][Full Text] [Related]
52. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
[TBL] [Abstract][Full Text] [Related]
53. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
[TBL] [Abstract][Full Text] [Related]
54. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
55. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy.
Ohrvall U; Westlin JE; Nilsson S; Juhlin C; Rastad J; Lundqvist H; Akerström G
Cancer; 1997 Dec; 80(12 Suppl):2490-4. PubMed ID: 9406700
[TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors.
Gibril F; Jensen RT
Yale J Biol Med; 1997; 70(5-6):509-22. PubMed ID: 9825478
[TBL] [Abstract][Full Text] [Related]
57. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study.
Kaemmerer D; Prasad V; Daffner W; Haugvik SP; Senftleben S; Baum RP; Hommann M
Clin Nucl Med; 2012 Feb; 37(2):142-7. PubMed ID: 22228336
[TBL] [Abstract][Full Text] [Related]
58. Somatostatin receptor imaging: a preliminary experience in forty-nine patients.
Giammarile F; Baudin E; Tenenbaum F; Lumbroso J; Schlumberger M; Rougier P; Ruffie P; Guigay J; Ducreux ML; Parmentier C
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):121-3. PubMed ID: 9002768
[TBL] [Abstract][Full Text] [Related]
59. Preferential localization of regional metastases from gastroenteropancreatic endocrine tumors with somatostatin-receptor scintigraphy.
MacGillivray DC; Mumtaz MA; Kurtzman SH; Spencer RP; Weiner RE; Malchoff CD
Arch Surg; 1996 Dec; 131(12):1338-42. PubMed ID: 8956777
[TBL] [Abstract][Full Text] [Related]
60. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
Cuccurullo V; Di Stasio GD; Mansi L
Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
